Abstract

Breast cancer is a leading cause of cancer-related morbidity and mortality among women worldwide, with hormonal factors playing a crucial role in its pathogenesis and treatment. This review explores the intersection of hormone therapy and breast cancer outcomes, focusing on the use of estrogen receptor modulators and aromatase inhibitors. We analyze the efficacy of hormone therapies in improving disease-free and overall survival rates, particularly in estrogen receptor-positive (ER+) breast cancer. Additionally, we examine the associated risks, including endometrial cancer and thromboembolic events, alongside the impact of treatment on patients' quality of life. The findings highlight the importance of personalized treatment strategies and adherence to therapy in optimizing patient outcomes. By understanding the multifaceted relationship between hormone therapy and breast cancer, clinicians can better navigate treatment options and improve care for patients with this complex disease.